Superworth

Biofrontera profit margin BFRI

Gross, operating and net profit as a share of revenue over the last twelve months, from 2021.

Net margin, 12 months
−13.8%
Operating margin, 12 months
−14.2%
Net margin on a year earlier
+28.6 pts
Peer median
9.2%

Over the twelve months to Jun 30, 2026, Biofrontera kept −13.8% of its revenue as net profit, with an operating margin of −14.2% and a gross margin of 79.3%.

Five years earlier its net margin was −46.2%.

The median for 3 large drugmakers of a similar size is 9.2%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025−25.3%−27.2%73.7%
FY2024−47.6%−46.1%50.1%
FY2023−59.1%−66.6%48.8%
FY2022−2.2%−64.8%47.0%
FY2021n/an/a47.1%
FY2020n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−13.8%+28.6 pts−14.2%
Q1 FY26−25.7%+4.7 pts−25.7%
Q4 FY25−25.3%+22.3 pts−27.2%
Q3 FY25−47.3%−11.0 pts−47.4%
Q2 FY25−42.3%−4.0 pts−41.6%
Q1 FY25−30.3%+39.1 pts−42.9%
Q4 FY24−47.6%+11.5 pts−46.1%
Q3 FY24−36.3%+42.3 pts−54.8%
Q2 FY24−38.3%+39.7 pts−54.0%
Q1 FY24−69.4%−20.0 pts−68.1%
Q4 FY23−59.1%−56.9 pts−66.6%
Q3 FY23−78.6%−34.0 pts−72.7%

Against its peers

Companies in Drug Manufacturers - General nearest Biofrontera's size, closest first, today.

CompanyProfit margin
BFRIBiofrontera−13.8%
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics15.7%
LFVNLifevantage2.8%
Peer median9.2%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Biofrontera

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.